(VOVWORLD) - Johnson & Johnson said on Thursday the US Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer.
The therapy, Talvey, is designed to bring a cancer cell and an immune cell together so the body’s immune system can kill the cancer.
Talvey will be sold at a list price of 45,000 USD per month, the company told Reuters, adding the price could vary based on a patient’s weight, prescribed dosing and treatment duration.
J&J estimates a pricing range of 270,000 USD to 360,000 USD for an average treatment duration of six to eight months. The company expects to make the therapy available to patients within three weeks.
Talvey was approved as a weekly or biweekly injection given under-the-skin to treat patients with relapsed multiple myeloma who have received at least four prior lines of treatment.